Literature DB >> 23589412

Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients.

L Gossec1, F Salejan, H Nataf, M Nguyen, V Gaud-Listrat, C Hudry, P Breuillard, E Dernis, P Boumier, M Durandin-Truffinet, J Fannius, J Fechtenbaum, M-A Izou-Fouillot, S Labatide-Alanore, A Lebrun, P LeDevic, P LeGoux, A Sacchi, C Salliot, L Sparsa, F Lecoq d'André, M Dougados.   

Abstract

OBJECTIVE: An annual assessment of cardiovascular (CV) risk factors in rheumatoid arthritis (RA) is recommended, but its practical modalities have not been determined. The objective was to assess the feasibility and usefulness of a standardized CV risk assessment in RA, performed by rheumatologists during outpatient clinics.
METHODS: We used a cross-sectional design within a network of rheumatologists. Each rheumatologist included 5 consecutive unselected patients with definite RA. Data collection included standardized assessment of CV risk factors: blood pressure, interpretation of glycemia and of lipid levels, and calculation of the Framingham CV risk score. Outcome criteria included feasibility (missing data and time taken to assess the patients) and usefulness (the CV risk assessment was considered useful if at least 1 modifiable and previously unknown CV risk factor was evidenced).
RESULTS: Twenty-two rheumatologists (77% in office-based practice) assessed 110 RA patients. The mean ± SD age was 57 ± 10 years, and the mean ± SD RA duration was 11 ± 9 years; 50 patients (45%) were treated with biologic agents, and 76% were women. Regarding feasibility, missing data were most frequent for glycemia (27% of patients) and cholesterolemia (14% of patients). The mean ± SD duration of the CV risk assessment was 15 ± 5 minutes. The CV risk assessment was considered useful in 33 patients (30%), evidencing dyslipidemia (15% of patients) or high blood pressure (9% of patients) as the most frequently previously unknown CV risk factor.
CONCLUSION: The assessment of CV risk factors is feasible, but labor intensive, during an outpatient rheumatology clinic. This assessment identified modifiable CV risk factors in 30% of the patients. These results suggest that RA patients are not sufficiently assessed and treated for CV risk factors.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 23589412     DOI: 10.1002/acr.21935

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  14 in total

1.  Development of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process.

Authors:  Claire E H Barber; Deborah A Marshall; Nanette Alvarez; G B John Mancini; Diane Lacaille; Stephanie Keeling; J Antonio Aviña-Zubieta; Dmitry Khodyakov; Cheryl Barnabe; Peter Faris; Alexa Smith; Raheem Noormohamed; Glen Hazlewood; Liam O Martin; John M Esdaile
Journal:  J Rheumatol       Date:  2015-07-15       Impact factor: 4.666

2.  [Collation of comorbidities: core competence of internist rheumatologists].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

3.  Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study.

Authors:  F C Ernste; M Sánchez-Menéndez; K M Wilton; C S Crowson; E L Matteson; H Maradit Kremers
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

4.  Cardiovascular risk factors' behavior during the early stages of the disease, in Hispanic rheumatoid arthritis patients: a cohort study.

Authors:  Irazú Contreras-Yáñez; Guillermo Guaracha-Basáñez; Virginia Pascual-Ramos
Journal:  Rheumatol Int       Date:  2019-10-12       Impact factor: 2.631

5.  The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis.

Authors:  Yael Luck; Murray Baron; Sonia Bardakjian; Laeora Berkson; Maura Buchignani; Sabrina Fallavolita; Frédérique Giac; Geneviève Gyger; Solène Tatibouet; Marie Hudson
Journal:  Clin Rheumatol       Date:  2014-02-15       Impact factor: 2.980

6.  EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic.

Authors:  Eirik Ikdahl; Silvia Rollefstad; Inge C Olsen; Tore K Kvien; Inger Johanne Widding Hansen; Dag Magnar Soldal; Glenn Haugeberg; Anne Grete Semb
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

Review 7.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

8.  Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.

Authors:  Yvette Meissner; Angela Zink; Jörn Kekow; Karin Rockwitz; Anke Liebhaber; Silke Zinke; Kerstin Gerhold; Adrian Richter; Joachim Listing; Anja Strangfeld
Journal:  Arthritis Res Ther       Date:  2016-08-05       Impact factor: 5.156

9.  Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).

Authors:  Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay
Journal:  Ann Rheum Dis       Date:  2013-10-04       Impact factor: 19.103

10.  Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts.

Authors:  Ana Maria Gherghe; Maxime Dougados; Bernard Combe; Robert Landewé; Carina Mihai; Francis Berenbaum; Xavier Mariette; Ron Wolterbeek; Désirée van der Heijde
Journal:  RMD Open       Date:  2015-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.